News Novartis adds to cancer reach with $3.9 billion acquisition Novartis backs ambition to be oncology world-leader
News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News Novartis joins with Berkeley to tackle "undruggable" targets Project will focus on areas such as cancer and infectious diseases
News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
News New Novartis blood cancer drug approved in EU Rydapt approved in mastocytosis, related blood cancers, and AML
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
